Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. · ¶6

That was error. The central question is whether Amarin plausibly alleged that Hikma actively encouraged infringing uses, not merely whether doctors could plausibly read the alleged statements as instructions to infringe. We therefore reverse the judgment of the Federal Circuit and remand the case for further proceedings.

slip opinion
Source edition
Passage preview. Read in context for the complete text, notes and references.